In This Section

Program

Please note that this meeting will take place as an in-person event in Philadelphia and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Wednesday, June 24

Thursday, June 25

Friday, June 26

Saturday, June 27

Wednesday, June 24

REGISTRATION

1-7 p.m.

WELCOME AND OPENING Keynote

  • 5 p.m. | Welcome and Introduction of Keynote Speaker
    Michael Green, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:10 p.m. | Opening Keynote Lecture
    Ron Levy, Stanford University, Stanford, California

Plenary Session 1: Antibodies through the eras

6-7:50 p.m.

  • 6 p.m. | Dave Maloney, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 6:30 p.m. | Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, New York
  • 7 p.m. | Bispecific antibodies in B-cell lymphomas: Redefining immune engagement in the therapeutic landscape
    Elicia Penuel, Genentech/Roche, San Francisco, California
  • 7:30 p.m. | Panel Discussion/Q&A

Reception

7:50-9:30 p.m.

Thursday, June 25

Breakfast

7-8 a.m.

Workshop: AI in lymphoma: foundation models and beyond

7:15-7:45 a.m.

  • Jansen Seheult, Mayo Clinic, Rochester, Minnesota, Minneapolis 

Plenary Session 2: Next Generation Clinical Assessment

8-9:50 a.m.

  • 8 a.m. | Davide Rossi, Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
  • 8:30 a.m. | Genetics to inform therapy in lymphoma
    Margaret Shipp, Dana Farber Cancer Institute, Boston, Massachusetts
  • 9 a.m. | Integrating the microenvironment and omics into clinical workflows
    Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:30 a.m. | Panel Discussion/Q&A

Break

9:50-10:10 a.m.

Plenary Session 3: The Lymphoma Microenvironment

10:10 a.m.-12 p.m.

  • 10:10 a.m. | Sandrine Roulland, Centre d’Immunologie de Marseille-Luminy, Marseille, France
  • 10:40 a.m. | Using the microenvironment to predict response to therapy
    Justin Kline, University of Chicago, Chicago, Illinois
  • 11:10 a.m. | Hodgkin lymphoma tumor microenvironment
    Christian Steidl, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  • 11:40 | Panel Discussion/Q&A

Lunch

12-2 p.m.

Plenary Session 4: Spatial Analysis of Lymphoma

2-3:50 p.m.

  • 2 p.m. | Dark zone lymphomas
    David Scott, University of British Columbia, Vancouver, British Columbia, Canada
  • 2:30 p.m. | Transformation
    Erin Parry, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 3 p.m. | Decoding lymphoma morphology with computer vision: A foundational approach
      Jansen Seheult, Mayo Clinic, Rochester, Minnesota, Minneapolis
  • 3:30 p.m. | Panel Discussion/Q&A

Break

3:50-4:10 p.m.

Spotlight on Proffered Abstracts

4:10-5:10 p.m.

  • 4:10 p.m. | Cytokine-linked stromal remodeling in transformed follicular lymphoma impacts macrophage function and can be detected non-invasively
    Laura Beckmann, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:16 p.m. | Bcl6-driven Cd70 -deficient Diffuse Large B-cell Lymphomas originate from innate-like cells with blunted CD4+ cytotoxic T-cell immune surveillance
    Elisa Mandato, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:21 p.m. | BTG1 mutation induces an age-associated B cell precursor population with extranodal and brain-infiltrating potential in diffuse large B cell lymphoma via interleukin-21 hypersensitivity
    Yulai Zhou, Yale University, New Haven, Connecticut
  • 4:27 p.m. | BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials
    Quinlan Sievers, Memorial Sloan Kettering Cancer Center, New York, New York
  • 4:34 p.m. | Mutant FOXO1 licenses MYC transformation of human germinal center B cells into dark-zone MYC-BCL2 high-grade B cell lymphomas
    Sabrina Giampaolo, The AIRC Institute of Molecular Oncology, Milano, Italy
  • 4:41 p.m. | C5ORF30/MACIR is a regulator of HLA-DR expression and immune evasion in high-risk DLBCL
    Anand Jeyasekharan, National University of Singapore, Singapore, Singapore
  • 4:47 p.m. | Mechanisms and impact of bystander killing by CAR T cells
    Joanna Chorazeczewski, University of Chicago, Chicago, Illinois

Poster Session

5:30-7:30 p.m.

Friday, June 26

Breakfast

7-8 a.m.

Workshop: ctDNA analyses of lymphoid malignancies

7:15-7:45 a.m.

  • Mark Roshchewski, Memorial Sloan Kettering Cancer, New York, New York

Plenary Session 5: New Targeted Therapeutic Strategies in Lymphoma

8-9:50 a.m.

  • 8 a.m. | Targeting BTK in CLL and other B-cell malignancies: Continuous progress with a continuous therapy
    Kerry Rogers, Ohio State University, Columbus, Ohio 
  • 8:30 a.m. | Multitargeted combination strategies to cure patients with large B-cell lymphoma
    Mark Roschewski, Memorial Sloan Kettering Cancer Center, New York, New York
  • 9 a.m. | Integrating novel agents into rational combinations
    Jason Westin, The University of Texas MD Anderson Cancer Center, Houston, Texas 
  • 9:30 a.m. | Panel Discussion/Q&A

break

9:50-10:10 a.m.

Plenary Session 6: Degraders in Lymphoma

10:10 a.m.-12 p.m.

  • 10:10 a.m. | Exploiting the E3 ligase FBXO21 as a novel therapeutic target and degrader in lymphoma
    Shannon Buckley, University of Utah, Salt Lake City, Utah
  • 10:40 a.m. | Resistance to BTK degraders
    Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland
  • 11:10 a.m. | Justin Taylor, University of Miami Miller School of Medicine, Miami, Florida
  • 11:40 p.m. | Panel Discussion/Q&A

Lunch on Own

12-2 p.m.

Plenary Session 7: Rare Lymphomas

2-4:20 p.m.

  • 2 p.m. | TP53-independent risk stratification in mantle cell lymphoma using a novel gene expression signature
    Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • 2:30 p.m. | Navigating the landscape of peripheral T-cell lymphomas
    Teresa Palomero, Columbia University, New York, New York
  • 3 p.m. | Updates on the treatment of primary CNS lymphoma
    Christian Grommes, Memorial Sloan Kettering Cancer Center, New York, New York
  • 3:30 p.m. | Panel Discussion/Q&A

coffee break

3:50-4:10 p.m.

Plenary Session 8: Advances in Cell Therapy

4:10-6 p.m.

  • 4:10 p.m. | Novel CAR-T cells in lymphoma
    Marcela Maus, Massachusetts General Hospital, Boston, Massachusetts
  • 4:40 p.m. | Armored CAR T cells
    Sarwish Rafiq, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • 5:10 p.m. | Analysis of site-specific CAR T cell efficacy in LBCL and development of novel engineering strategies
    Laura Evgin, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  • 5:40 p.m. | Panel Discussion/Q&A

break

6-6:20 p.m.

CAR T-Cell Emerging Toxicities

Organized in collaboration with the Hematologic Malignancies Working Group

6:20-7:30 p.m.

Moderator: Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia

  • 6:20 p.m. | Topic Introduction
    David Porter, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
  • 6:30 p.m. | T-cell lymphomas after CAR-T
    Premal Lulla, Baylor College of Medicine, Houston, Texas
  • 6:40 p.m. | Panel Discussion
    David Porter, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
    Premal Lulla, Baylor College of Medicine, Houston, Texas, United States
    Marcela Maus, Massachusetts General Hospital, Boston, Massachusetts
Saturday, June 27

Breakfast

7-8 a.m.

Workshop: Leveraging Spatial Technologies in Lymphoma

7:15-7:45 a.m.

  • Anand Jeyasekharan, National University of Singapore, Singapore, Singapore

Closing Keynote Lecture

8-9 a.m.

  • Michel Nussenzweig, Rockefeller University, New York, New York

Plenary Session 9: The Origins of Lymphoma

9-10:50 a.m.

  • 9 a.m. | Cells of origin for lymphoma
    Dinis Pedro Parente Calado, Francis Crick Institute, London, England, United Kingdom
  • 9:30 a.m. | Ari Melnick, Josep Carreras Institute, Badalona, Catalonia, Spain
  • 10 a.m. | Mouse models of mantle cell lymphoma
    Ron Jachimowicz, University Hospital Cologne, Germany
  • 10:30 a.m. | Panel Discussion / Q&A

coffee break

10:50-11:10 a.m.

Plenary Session 10: Epigenetics

11:10-1:15 p.m.

  • 11:10 a.m. | Targeting the BCL6 transcription factor in lymphoma
    Michael Green, The University of Texas MD Anderson Cancer Center, Houston, Texas  
  • 11:40 a.m. | Epigenetic regulation of the lymphoma microenvironment: from single-cell behavioral reprogramming to systems-level niche corruption
    Wendy Beguelin, New York University, New York, New York
  • 12:10 p.m. | Laura Pasqualucci, Columbia University, New York, New York
  • 12:40 p.m. | Panel Discussion / Q&A

Closing Remarks

1 p.m.